Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 10/20 | 0.45 |
| ▸ | MAOA | P21397 | 9/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1198034 | 0.88 | CRBN (0.51) | SMYD3MAOBMAOANPC1MAPK13 | |
| SCHEMBL18153040 | 0.85 | CA9 (0.51) | CA9SMYD3MAOBMAOANPC1 | |
| SCHEMBL10836010 | 0.82 | SMYD3 (0.49) | CA9SMYD3MAOBMAOANPC1 | |
| SCHEMBL1144991 | 0.81 | SMYD3 (0.59) | CA9SMYD3MAOBMAOANPC1 | |
| SCHEMBL9379920 | 0.81 | CA9 (0.62) | CA9SMYD3MAOBMAOANPC1 | |
| SCHEMBL2218590 | 0.80 | CA9 (0.56) | CA9SMYD3MAOBMAOANPC1 | |
| Hydrochloric Acid SCHEMBL27785028 | 0.80 | SMYD3 (0.58) | CA9SMYD3MAOBMAOANPC1 | |
| SCHEMBL29003155 | 0.79 | AKR1C4 (0.51) | SMYD3CRBNMAPT | |
| SCHEMBL2306726 | 0.77 | EPHX2 (0.59) | SMYD3 | |
| SCHEMBL15927500 | 0.77 | PTPN1 (0.52) | NPC1ALDH1A1MAPTPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283464-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3283464-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10081617-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3283464-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168098-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168098-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-2102189-B1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8410155-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100016316-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-21 | — | — | US | disclosed |
| EP-2102189-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008076805-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
| US-4619932-A | CENTRAL NERVOUS SYSTEM CONTROLLERS; ANTI-SCHIZOPHRENIA AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-28 | — | — | US | disclosed |
| US-4567187-A | CENTRAL NERVOUS SYSTEM | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-28 | — | — | US | disclosed |
| US-4460593-A | Carbostyril derivatives, and central nervous system controlling agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-07-17 | — | — | US | disclosed |
| US-4455422-A | ANTIHISTAMINES, CNS CONTROLLERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079743-A1 | FACTOR XIa INHIBITORS | F11, F2, TFPI | CA9 640/4885SMYD3 3451/4885MAOB 916/4885 |
| US-20100016316-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | F12, TFPI, F11 | CA9 2543/4885SMYD3 2580/4885MAOB 471/4885 |
| US-10081617-B2 | Factor XIa inhibitors | F11, F2, TFPI | CA9 640/4885SMYD3 3451/4885MAOB 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.